Gilenya was first approved in 2010 and has been a big brand for Novartis, although it is facing strong competition from newer drugs such as Roche's Ocrevus (ocrelizumab), Merck KGaA's Mavenclad ...
It will not be the most expensive but it will not be the cheapest – a very effective drug at the same list price as Gilenya.” When NICE assessed Gilenya back in 2012, it said the drug costs ...
A US court has ordered generic drug makers to stop selling a copy of Gilenya in US. The annual sales of Gilenya, a drug used to treat multiple sclerosis, was about $3.3 billion in 2018.
Building upon the established success of Novartis’ Gilenya in Canada, these next-generation disease-modifying therapies (DMTs) offer proven efficacy for MS subtypes with high unmet need ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback